10-Q: Qrons Inc. Reports Increased Net Loss in Second Quarter 2024 Amidst Ongoing Development

Qrons Inc. reported a net loss of $109,266 for the three months ended June 30, 2024, a significant increase compared to the $12,746 loss in the same period of 2023, primarily due to increased research and development expenses.

Summary

• Qrons Inc. reported a net loss of $109,266 for the three months ended June 30, 2024, and a net loss of $151,882 for the six months ended June 30, 2024.
• The company has not generated any revenue since its inception and does not expect to generate revenue from product sales in the near future.
• Operating expenses increased significantly, primarily due to a rise in research and development costs, which included stock-based compensation.
• The company's cash and cash equivalents stood at $11,707 as of June 30, 2024, compared to $420 at the end of 2023.
• Qrons is relying on related party advances to fund operations, with $42,500 received in the first six months of 2024.
• The company is exploring strategic alliances and additional financing options to support its research and development activities.
• Qrons has a going concern issue due to recurring losses and limited operations.

Sentiment

Score: 3

Explanation: The document indicates a concerning financial situation with increasing losses, no revenue, and reliance on related party funding. The going concern issue and ineffective internal controls further contribute to a negative outlook.

Positives

• The company's cash position improved to $11,707 as of June 30, 2024, from $420 at the end of 2023.
• Qrons is actively exploring strategic alliances and additional financing options to support its research and development activities.

Negatives

• The company has not generated any revenue since its inception and does not expect to generate revenue from product sales in the near future.
• Qrons reported a significant increase in net losses for both the three and six months ended June 30, 2024.
• Operating expenses have increased substantially, primarily due to research and development costs.
• The company is heavily reliant on related party advances to fund its operations.
• Qrons has a going concern issue due to recurring losses and limited operations.

Risks

• The company's ability to continue as a going concern is in doubt due to recurring losses and limited operations.
• Qrons is dependent on securing additional financing to fund its operations and research and development activities.
• There is no guarantee that the company will be able to commercialize its product candidates or generate revenue.
• The company's internal controls and procedures are not effective due to inadequate segregation of duties and lack of a formal audit committee.
• The company is subject to significant cash penalties if it defaults on the Quick Note or fails to issue shares in a timely manner.

Future Outlook

The company expects to require substantial additional funds for operations, the service of debt, and to fund its business objectives. They are exploring strategic alliances and additional financing options.

Management Comments

• The company has relied primarily on its two co-founders to manage its day-to-day business and has outsourced professional services to third parties in an effort to maintain lower operational costs.
• The company's officers or principal shareholders are committed to making advances or loans to pay for ongoing operational costs.

Industry Context

Qrons is operating in the biotechnology sector, which is characterized by high research and development costs and long development timelines. The company's focus on neuronal and infectious diseases aligns with growing global health concerns, but it faces competition from established pharmaceutical and biotech companies.

Comparison to Industry Standards

• Qrons' lack of revenue is typical for early-stage biotech companies focused on research and development.
• The company's reliance on related party funding is not uncommon for startups, but it highlights the need for external investment.
• The increase in research and development expenses is consistent with the nature of biotech development, but the lack of revenue generation is a concern.
• Compared to companies like BioMarin Pharmaceutical Inc. or Vertex Pharmaceuticals Incorporated, which have established revenue streams, Qrons is in a much earlier stage of development and faces significant financial challenges.
• The company's focus on antibiotic-resistant bacteria and traumatic brain injuries is aligned with current global health priorities, similar to companies like Achaogen (now defunct) and BrainStorm Cell Therapeutics Inc., but Qrons is at a much earlier stage of development.

Corporate Governance

Related Party Transactions

• The company received $42,500 in proceeds from related party advances during the six months ended June 30, 2024.
• The company has demand loans from related parties totaling $85,873 as of June 30, 2024.
• Advances from related parties totaled $467,000 as of June 30, 2024.
• Jonah Meer, the company's CEO, made payments of $21,818 to various vendors during the six months ended June 30, 2024.
• Ido Merfeld, the company's President, made $0 payments to various vendors during the six months ended June 30, 2024.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern issue.
• Employees may be affected by potential cost-cutting measures or delays in operations.
• Customers and suppliers are not directly impacted at this stage, as the company is still in the research and development phase.
• Creditors face increased risk due to the company's financial difficulties.

Next Steps

• The company will continue to explore sources of debt and equity financing.
• Qrons will continue discussions for a potential strategic alliance in the biotechnology field.
• The company will continue to monitor the effectiveness of its actions to mitigate material weaknesses in internal controls.

Key Dates

Keywords

biotechnology, research and development, net loss, operating expenses, convertible notes, stock options, related party transactions, going concern, derivative liabilities, financing